Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dimesna - Lantern Pharma

Drug Profile

Dimesna - Lantern Pharma

Alternative Names: BNP 7787; LP 300; Tavocept

Latest Information Update: 24 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNumerik Pharmaceuticals
  • Developer BioNumerik Pharmaceuticals; Lantern Pharma
  • Class Alkanesulfonates; Antineoplastics; Chemoprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Glutaredoxin modulators; Thioredoxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lung cancer
  • Phase II Non-small cell lung cancer
  • No development reported Peripheral nervous system diseases

Most Recent Events

  • 22 Apr 2024 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, Japan (IV)
  • 22 Apr 2024 Lantern Pharma receives regulatory approval to initiate the phase II HARMONIC trial in Non-small cell lung cancer in Taiwan and Japan
  • 20 Mar 2023 Lantern Pharma has patent protection for dimesna in US, Canada, Brazil, Mexico, EU, China, Japan and Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top